EHA 2025 | An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the encouraging results of the CADENZA trial (NCT03386513), a study assessing the efficacy and safety of pivekimab sunirine, a novel CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). He highlights the inclusion of patients with prior or concomitant hematologic malignancy (PCHM), a notable aspect of the research. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m very excited to be here at EHA 2025 in Milan, Italy, where I just presented the results on behalf of my colleagues of the CADENZA study. Briefly, the CADENZA study is an international Phase I/II program for pivekimab sunirine, or PVEK, which is a novel CD123 targeted therapy. In very brief, what we showed is in this large study, 84 patients, of whom 33 were frontline, 51 relapsed/refractory...
I’m very excited to be here at EHA 2025 in Milan, Italy, where I just presented the results on behalf of my colleagues of the CADENZA study. Briefly, the CADENZA study is an international Phase I/II program for pivekimab sunirine, or PVEK, which is a novel CD123 targeted therapy. In very brief, what we showed is in this large study, 84 patients, of whom 33 were frontline, 51 relapsed/refractory. We showed high and durable response rates among the frontline treated patients, so that’s a 70% CRc rate frontline, and then also it’s a very safe and feasible drug. In addition, about half the patients who responded in the frontline setting were able to go to transplant, notable as it’s an older group of patients. And finally, I’m very proud that we included patients with so-called PCHM, which is prior or concomitant hematologic malignancy, and there was a subgroup of those patients analyzed as well. So overall, we believe a potentially practice-changing paradigm that was presented here, and hopefully looking forward to new options for patients with BPDCN.
I think what’s important about projects such as this one that highlight an ultra-rare disease really highlights the intersection of the stakeholders, medical education information platforms such as yours, all the stakeholders in an international community around the world for the rarest of the rare most ultra rare diseases and so I just want to give a shout out to all those who are involved in medical education medical information such as VJHemOnc and others who help us particularly during COVID pandemic time to get the message out there and that’s how how you help to enroll on these rare disease studies, how you get the word out there, how you get referrals. And I want us to continue to keep working together as an international community to give hope to patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
